Clinical-stage biotechnology company Nektar Therapeutics (NKTR) saw its stock price surge on Monday, following the company’s announcement of positive results from a clinical trial for a drug targeting patients with severe to very severe alopecia areata. Boosted by this news, the company’s stock price rose more than 18% on the day.
Before the market opened on Monday, Nektar Therapeutics released the results of its Phase 2b clinical study of the drug rezpegaldesleukin for patients with severe to very severe alopecia areata. The trial found that patients who had already responded to the treatment experienced further increases in hair growth over time.
This finding brings significant optimism for the future of rezpegaldesleukin. Last year, Nektar disappointed the market when the drug failed to show statistically significant efficacy over a 36-week treatment period. However, the company subsequently discovered that four patients who received the drug did not meet the treatment criteria. The latest 52-week trial excluded these four individuals.
Nektar, which focuses on developing immunology therapies (such as rezpegaldesleukin), stated that it will advance the drug into later-stage clinical trials.
This marks a major turnaround for both rezpegaldesleukin and its developer, Nektar Therapeutics. Alopecia areata is a common autoimmune disease that affects millions of people in the United States alone. Leveraging its innovative scientific approach, the drug holds substantial potential.
Nektar Therapeutics is one of the winners of 2025, with this clinical-stage biotech company seeing its stock soar due to positive clinical progress. Its drug rezpegaldesleukin is a promising clinical asset with the potential to make waves in immunology, one of the industry’s largest therapeutic areas. If the company can continue its recent clinical trial success, its stock price could surge again in 2026.
Furthermore, Nektar Therapeutics also announced positive Phase 2b data for rezpegaldesleukin in treating eczema this year. Eczema represents a massive market, home to global blockbuster drugs such as Dupixent and Rinvoq.
However, as a preclinical to commercial-stage biotech company with no marketed products and sustained net losses, Nektar Therapeutics still carries high risk. Even with positive Phase 2 results, rezpegaldesleukin could still fail in later-stage studies, which would likely cause the company’s stock price to plummet.
Conclusion: Positive results from the Phase 2b clinical trial of Nektar Therapeutics’ hair loss treatment rezpegaldesleukin drove the company’s stock price up more than 18% in a single day, reigniting market hopes for its potential in the immunology field. However, the company currently has no marketed products, and the drug’s subsequent clinical trials still carry the risk of failure, requiring investors to maintain caution.
